The present invention relates to the expression of polypeptides using Yarrowia lipolytica, in particular the secretion of expressed polypeptides into either the extracellular space or the surface of the Y. lipolytica host cell wall. The invention also extends to the use of the polypeptides so expressed in biotechnological applications. The present invention provides an expression construct for the expression of polypeptides using at least a single Yarrowia lipolytica yeast cell, the expression construct having at least one expression cassette, the expression cassette including an acid extracellular protease secretion signal sequence and flanking zeta sequence recombination sites.
|
1. A polypeptide that is expressed by recombinant Yarrowia lipolytica using a genetic construct codon-optimized for expression of the polypeptide in Yarrowia lipolytica, the construct comprising an acid extracellular protease secretion signal sequence, flanking zeta sequence recombination sites, at least one promoter, at least one terminator, and a nucleic acid sequence encoding a polypeptide;
wherein the polypeptide is an antigen derived from a subunit of a beak and feather disease virus (BFDV) coat protein;
wherein the antigen derived from the subunit of the BFDV coat protein retains antigenicity when expressed by the genetic construct in Yarrowia lipolytica; and
wherein the polypeptide is encoded by SEQ ID NO: 5.
3. The diagnostic kit of
5. The medicament of
7. The vaccine of
8. The vaccine of
|
|||||||||||||||||||||||||||||||
This application is a divisional application of co-pending application Ser. No. 14/870,985, filed Sep. 30, 2015; which claims priority to South African Application No. 2014/07098, dated Sep. 30, 2014; both of which are incorporated herein in their entirety.
The Sequence Listing for this application is labSeqList-30Sep15-ST25.txt”, which was created on Sep. 30, 2015, and is 19 KB. The entire content is incorporated herein by reference in its entirety.
The present invention relates to the expression of polypeptides using Yarrowia lipolytica, and in particular the secretion of expressed polypeptides into either the extracellular space or on to the surface of the Y. lipolytica host cell wall. The invention also extends to, but is not limited to, the use of the polypeptides so expressed in medical and veterinary biotechnological applications.
Y. lipolytica is a dimorphic, aerobic yeast generally considered non-pathogenic due to its low maximal growth temperature. In light of this, it has been classified by the Food and Drug Agency as generally regarded as safe. This organism is notable for its unusual metabolism—it can metabolise few sugars but is able to break down and use a number of hydrophobic substances, including long-chain fatty acids. The organism is easy to transform, with good transformation efficiency and stability being observed. In addition, development of recombinant promoters in this organism has allowed high levels of expression to be achieved in nearly all growth mediums (Nicaud et al (2002); FEMS Yeast Research; volume 2; pg 371-379).
The use of yeasts such as Y. lipolytica for expression of proteins is necessary due to the inability of bacterial expression systems to perform mammalian post-translational modification of proteins.
Yeasts, along with Eukaryotic cell cultures and genetically engineered plants, are able to perform some or all of these modifications and thus produce a superior product. Yeasts, especially, have a number of advantages when used in this manner: a well-understood culture methodology, purification regime, rapid biomass conversion and the ability to perform most mammalian post-translational modifications. This facility can also be improved using genetic engineering—for instance, the insertion of human genes catalysing glycosylation—for which yeasts are also admirably suited.
However, the most commonly used representative of the yeast family—Saccharomyces cerevisiae—has certain limitations, such as low heterologous protein production in culture and hyperglycosylation of recombinant proteins. The potential advantages of other yeast species as expression systems, including more mammalian-like post-translational modifications of proteins and the ability to use other carbon sources, has lead research into these organisms as alternatives to S. cerevisiae. Four of these species; Hansenula polymorphs, Pichia pastoris, Arxula adeninivorans and Yarrowia lipolytica; were reviewed in terms of their comparative advantages and disadvantages as expression systems (Gellisen et al (2005); FEMS Yeast Research; volume 5; pg 1079-1096). In this review, Y. lipolytica was identified alongside A. adeninivorans as having promising potential for industrial processes.
Accordingly, there is a need in the art for expression systems specific to Y. lipolytica for the production of polypeptides with biotechnological applications.
For the purposes of the present specification, the term “polypeptide” as used herein is understood as denoting peptides or proteins which comprise two or more amino acids bonded via peptide bonds.
The term “fusion polypeptide” or “fusion protein” refers to a polypeptide or protein which is constituted from sequences taken from more than one other polypeptide or protein, joined contiguously so that the sequences are expressed as a single polypeptide or protein.
The term “acid extracellular protease secretion signal sequence” as used herein is understood as referring to a nucleotide sequence which, when expressed as a polypeptide in fusion with another polypeptide or protein, will direct the cell to transport the fused protein into the extracellular space.
The term “zeta sequence recombination site” or “zeta element” as referred to herein refers to nucleotide sequences in the form of Long Terminal Repeats of the Ylt 1 retrotransposon. These sequences promote homologous integration of any attached genetic sequences into the yeast host genome, so long as the host genome also contains Ylt 1 retrotransposons. The retrotransposon can also be introduced into the genome of strains devoid of zeta elements, primarily by means of non-homologous recombination and random integration
The term “cell wall protein” refers to a polypeptide which, when expressed into the extracellular space by the host cell, anchors itself and any attached fusion polypeptides/proteins to the host cell wall.
The term “auxotrophic marker” refers to a nucleotide sequence which, when expressed by the host cell, allows it to manufacture a particular nutrient (usually an amino acid) endogenously. The marker serves as a positive selective aid when sequences carrying it are transformed into a host cell that is unable to manufacture the relevant nutrient.
According to a first aspect thereof, the present invention provides for a genetic construct for the expression of polypeptides in Yarrowia lipolytica the genetic construct including at least an acid extracellular protease secretion signal sequence and flanking zeta sequence recombination sites. In a preferred embodiment of the invention, the acid extracellular protease secretion signal is the nucleotide sequence of SEQ ID 1, or a fragment or fragments thereof. In a further preferred embodiment, the flanking zeta sequence recombination sites are the nucleotide sequence of SEQ ID 2, or a fragment or fragments thereof.
In an embodiment of the invention, the genetic construct includes at least one expression cassette, the expression cassette including the acid extracellular protease secretion signal sequence and flanking zeta sequence recombination sites. The genetic construct may further be in the form of an expression vector; typically an extrachromosomal genetic element such as a plasmid or bacteriophage genome that is used to introduce one or more genes into a host cell.
In an embodiment of the present invention, the genetic construct is a plasmid and the host cell is Y. lipolytica. In a preferred embodiment, the genetic construct is a plasmid which is pre-fragmented before integration with the host cell. It may be appreciated that a number of approaches may be used to fragment a plasmid. In a further preferred embodiment, the fragmentation is carried out using restriction endonucleases, as is known in the art. In a further preferred embodiment, these restriction endonucleases include, but are not limited to: SfiI, AvrII, BamHI, Acc651, KpnI, BglI, HindIII, BspEI and combinations thereof.
In an embodiment of the invention, the genetic construct may include a Y. lipolytica cell wall protein encoding element, located between a Multiple Cloning Site (MCS) or polypeptide encoding region and the terminator element of the expression cassette. In a preferred embodiment of the invention, the protein YI CWP110 (NCBI accession number: YALI0E18788 g) of nucleotide SEQ ID 3 is used as a cell wall protein encoding element.
The expression cassette referred to herein above comprises those genetic elements which are necessary for expression and/or co-expression of the polypeptide encoding region/s in the Y. lipolytica yeast host cell. In particular, the expression cassette includes at least one promoter element and at least one terminator element.
In a preferred embodiment of the invention, the hp4d recombinant promoter of SEQ ID 4 is used as a promoter element.
In an embodiment of the invention, the acid extracellular protease secretion signal sequence is located between the promoter element and polypeptide encoding region or MCS. The genetic construct may further include a MCS located between the acid extracellular protease secretion signal sequence and terminator element of the expression cassette. The MCS includes multiple recognition and digestion sites for Restriction Enzymes. In an embodiment of the invention, the MCS includes sites for known Restriction Enzymes, including sites selected from among: SfiI, AvrII, BamHI, Acc651, KpnI, BglI, HindIII and BspEI.
According to a second aspect thereof, the present invention provides for a method of transforming the Y. lipolytica host cell with an expression construct or combinations of expression constructs, the method including the steps of:
It should be understood that the design of the expression construct employed in the present invention may vary, and will depend on factors such as the non-yeast host cell and transfection approach being used to transfer the expression construct and expression cassette into the host cell. For instance, the number and type components (including the expression cassette, zeta flanking regions, auxotrophic marker elements and bacterial moiety elements) may vary. In an embodiment of the invention, the non-yeast host cell is a bacterial host cell.
In a preferred embodiment of the invention, the genetic construct is the pINA1317 (see
The expression construct may include one or more auxotrophic marker regions for the purposes of replication and selection in yeast host cells. In an embodiment of the invention, auxotrophic markers are selected from among the uracil (ura) and leucine (leu) auxotrophies. These may be used together as separate vectors in some strains to transform one such strain with more than one copy of the gene of interest or more than type of gene, encoding for different polypeptide products.
The expression construct may further include one or more bacterial moiety regions for the purposes of replication and selection in bacterial host cells. This region may then include flanking sites for Restriction Enzyme digestion, allowing excision and removal of the bacterial moiety prior to insertion of the expression construct into the yeast host cell.
In an embodiment of the invention, bacterial moieties are selected from among the bacterial antibiotic resistant gene constructs, the gene constructs including, but not limited to, constructs encoding Kanamycin resistance. In a further embodiment, the bacterial moieties include a bacterial origin of replication. The flanking Restriction Enzyme digestion site is selected from among the known restriction enzyme sites. In a preferred embodiment, the NotI site is used as a flanking Restriction Enzyme digestion site.
In an embodiment of the invention, the non-yeast host cell is of bacterial origin. The host cell is selected from the group consisting of Eschericia coli (E. coli), Bacillus subtilis and Thermus thermophilus. In an embodiment of the invention, E. coli JM109 (endA1, recA1, gyrA96, thi, hsdR17 (rk−, mk+), relA1, supE44, Δ(lac-proAB), [F′ traD36, proAB, laqIqZΔM15]) is employed as the bacterial host cell. In a preferred embodiment, top 10 competent E. coli cells or XL10 gold competent E. coli cells may employed as the bacterial host cell.
In an embodiment of the invention, the yeast host cell is selected from the group consisting of Y. lipolytica: Po1h (MatA, ura3-302, xpr2-322, axp1-2); Po1f (MatA, leu2-270, ura3-302, xpr2-322, axp-2); E129 (MatA, lys11-23, ura3-302, leu2-270, xpr2-322) and E150 (MatB, his-1, leu2-270, ura3-302, xpr2-322). In a preferred embodiment of the invention, Po1h is employed as the yeast host cell.
The host cell can be transformed using the described vectors by various methods (e.g. electroporation, transfection using calcium chloride, rubidium chloride, calcium phosphate, the lithium-acetate method, DEAE-dextran, microprojectile bombardment, lipofection, whisker-mediated transformation, and other methods) depending on the type of cellular host.
In an embodiment of the invention, the rubidium chloride method is employed for the bacterial host, while the lithium-acetate method is used for the yeast host.
Transformation to specific regions of the yeast host genome may be accomplished by the flanking zeta sequences. In an embodiment of the invention, site-specific homologous recombination of flanking zeta sequence sites on the expression cassette with corresponding sites in the Ylt1+ yeast host cell genome is targeted.
In a further embodiment of the invention, non-homologous recombination of flanking zeta sequence sites on the expression cassette integrates at random targets of the Ylt1− yeast host cell genome.
The transformed bacterial host cell is cultured on a culture medium under conditions favouring growth of the cells for propagation of the vector. In an embodiment of the invention, the culture medium is selected from the group consisting of Luria-Bertani (LB) liquid medium and LB agar. In a preferred embodiment, LB agar plates supplemented with kanamycin are used, followed by inoculation into liquid LB media supplemented with kanamycin. The culture conditions, such as temperature, pH and the like, will be apparent to the ordinary skilled artisan.
Bacterial cells are typically harvested by centrifugation, disrupted by physical or chemical means and the resulting crude extract retained for further purification.
The expression construct, described herein, may be isolated and purified by a variety of processes as known in the art. Exemplary procedures suitable for such recovery and purification include salt-and-alcohol methods and silica-column purification. In a preferred embodiment, the Sambrook method (SAMBROOK, J.; MACCALLUM, P. and RUSSELL, D. Molecular Cloning: A Laboratory Manual. 3rd. Cold Spring Harbor Press, NY, 2001. 2344 p. ISBN 0-87969-577-3) is used.
The transformed yeast host cell is cultured on a culture medium under conditions favouring the expression of the polypeptide. In an embodiment of the invention, the culture medium is selected from the group consisting of Yeast Extract Peptone Dextrose (YEPD) liquid medium and YEPD agar or the group consisting of Yeast Nitrogen Base (YNB) liquid medium and YNB agar. In a preferred embodiment, selective YNB medium is used. The culture conditions, such as temperature, pH and the like, will be apparent to the ordinary skilled artisan.
According to a third aspect thereof, the present invention provides for the use of expressed polypeptides secreted into the extracellular space by Y. lipolytica in biotechnological applications, the polypeptides including antigens.
The invention provides for the use of the foregoing polypeptides in biotechnological applications, including but not limited to vaccines, diagnostic kits or products, medicaments, antibiotic or antimicrobial formulations and nutritional additives.
In an embodiment of the invention, antigens for use in vaccine and diagnostic applications may be selected from among a range of candidates, including: beak and feather disease virus, Pigeon circovirus, E. coli pathotypes, Avibacterium paragallinarum, Newcastle disease virus, Infectious bronchitis virus, Infectious bursal disease virus, Chicken anaemia virus, Poultry Reovirus and Lacctococcus garvieae.
It should be understood that the design of the antigen for use as a vaccine component may depend on such factors as the size of polypeptide, the stability of the polypeptide, the degree of immunogenicity elicited by the polypeptide, the specificity of the immunogenic response elicited and the optimal codon sequence for a given host cell. The specific design of antigen for use in the above-mentioned candidates will be apparent to those skilled in the art.
In an embodiment of the invention, Psittacine Beak and Feather Disease Virus Coat Protein (BFDV CP) sequence of SEQ ID 5 is used to create components for a sub-unit vaccine against beak and feather disease virus. The vaccine may then be administered by methods including, but not limited to: intramuscular injection, addition of the vaccine components to food or drink or spraying.
In an embodiment of the invention, the foregoing polypeptides may be used to create components for a diagnostic kit. The diagnostic kit may be selected from a group including, but not limited to: rapid plate agglutination testing, direct Enzyme-Linked Immunosorbent Assay (ELISA), indirect ELISA, precipitation testing, complement fixation testing, neutralization testing and fluorescent antibody testing.
In an embodiment of the invention, the Psittacine BFDV CP sequence is used to create components for rapid plate agglutination tests and ELISA diagnostic kits against beak and feather disease virus antibodies in serum.
In an alternate embodiment of the invention, the Psittacine BFDV CP sequence is used to create components for a fluorescent antibody test and diagnostic kit against beak and feather virus disease antibodies in serum.
According to a sixth aspect thereof, the present invention provides for the use of polypeptides expressed as a fusion protein with a Y. lipolytica cell wall protein encoding element, the polypeptides including antigens.
The invention provides for the use of the foregoing polypeptides in biotechnological applications, including but not limited to vaccines, diagnostic kits or products, medicaments or antimicrobial formulations and nutritional additives.
In an embodiment of the invention, antigens for use in vaccine and diagnostic applications may be selected from among a range of candidates, including: beak and feather disease virus, Pigeon circovirus, E. coli pathotypes, Avibacterium paragallinarum, Newcastle disease virus, Infectious bronchitis virus, Infectious bursal disease virus, Chicken anaemia virus, Poultry Reovirus and Lacctococcus garvieae.
In a preferred embodiment of the invention, the Psittacine BFDV CP sequence is used to create a whole cell vaccine, inactivated cell vaccine or cell lysate vaccine and/or diagnostic kit components against beak and feather disease virus. The vaccine may then be administered by methods including, but not limited to: intramuscular injection, addition of the vaccine components to food or drink or spraying.
It should be understood that the design of the antigen for use as a vaccine component may depend such factors as the size of polypeptide, the stability of the polypeptide, the degree of immunogenicity elicited by the polypeptide, the specificity of the immunogenic response elicited and the optimal codon sequence for a given host cell. The specific design of antigen for use in the above-mentioned candidates will be apparent to those skilled in the art.
In an embodiment of the invention, the BFDV CP sequence is used to create whole-cell and inactivated yeast cell vaccines and diagnostic kit components against beak and feather disease virus. In a preferred embodiment of the invention, whole cells displaying Psittacine BFDV CP fusion sequences are used to create components for rapid plate agglutination and ELISA diagnostic kits against beak and feather disease virus antibodies in serum.
According to a seventh aspect thereof, there is provided a pharmaceutical preparation for use in the stimulation of immune response, comprising a therapeutically effective amount of at least one polypeptide, as identified herein, in combination with one or more pharmaceutically acceptable excipients, additives or carriers.
According to a eighth aspect thereof, there is provided the use of at least one polypeptide, as identified herein, in the manufacture of a medicament for the treatment, diagnosis and/or prevention of diseases and/or disorders.
The diseases and/or disorders referred to above may be selected from the group including, but not limited to: beak and feather disease, Young Bird Disease (YBD), E. coli pathotype infection, infectious coryza, Newcastle disease, infectious bronchitis, infectious bursal disease, chicken anaemia, Poultry Reovirus infection and lactococcosis.
These and other objects, features and advantages of the invention will become apparent to those skilled in the art following the detailed description of the invention as set out in the Examples.
The presently disclosed subject matter will now be described more fully hereinafter with reference to the accompanying Examples, in which representative embodiments are shown. The presently disclosed subject matter can, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the embodiments to those skilled in the art.
The invention was performed in accordance with the following steps.
Materials and Methods
Capsid Protein “Gene of Interest”
The gene encoding the BFDV CP was codon-optimized for expression in Yarrowia lipolytica, and synthesized by GeneArt. The initiation codon (CTG) and stop codon (TAA) were removed and SfiI (5′) and HindIII (3′) restriction endonuclease recognition sites were added to the sequence [AY450443—Beak and Feather disease virus isolate AFG3-ZA, complete genome]. The supplied lyophilised synthetic gene (5 μg plasmid DNA) was reconstituted in 50 μl 10 mM Tris-HCl (pH 8.0) upon arrival.
Strains and Media
Escherichia coli JM109 (endA1, recA1, gyrA96, thi, hsdR17 (rk−, mk+), relA1, supE44, Δ(lac-proAB), [F′ traD36, proAB, laqIqZΔM15]) cells were used for plasmid manipulations and propagation. Standard molecular biology techniques were used as described in Sambrook and Russel (2001), unless explicitly stated otherwise. The E. coli transformants were grown at 37° C. in 5.0 ml Luria-Bertani (LB) broth [0.5% (w/v) yeast extract, 1% (w/v) sodium chloride and 1% (w/v) tryptone] supplemented with 30 μg/ml of kanamycin and on LB-agar plates supplemented with 1.5% w/v agar and 30 μg/ml of kanamycin.
The Y. lipolytica yeast strains used was Po1h (MatA, ura3-302, xpr2-322, axp1-2). The yeast strain was supplied by CBAI, AgroParisTech, 78850 Thiverval-Grignon, France. The yeast strain was grown in 50 ml of YPD [1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) glucose] medium in 250 ml flasks at 28-30° C. Yeast transformants were grown on YNB-N5000 [0.17% (w/v) yeast nitrogen base without amino acids and ammonium sulphate, 1% (w/v) glucose and 0.5% (w/v) ammonium sulphate] or alternative Ura-selective medium [0.17% (w/v) yeast nitrogen base without amino acids and ammonium sulphate, 1% (w/v) glucose, 0.4% (w/v) ammonium chloride and 0.2% (w/v) CAS amino acids] plates at 28-30° C.
Other Yarrowia lipolytica strains besides Po1h that are included in this invention are Po1f (MatA, leu2-270, ura3-302, xpr2-322, axp-2); E129 (MatA, lys11-23, ura3-302, leu2-270, xpr2-322) and E150 (MatB, his-1, leu2-270, ura3-302, xpr2-322).
Plasmid/Expression Vector
The SURFACE DISPLAY EXPRESSION VECTOR is described as the plasmid pINA1317-YICWP110, while the SECRETORY EXPRESSION VECTOR is plasmid pINA1317 alone, i.e. without the gene encoding YICWP110. Both of these vectors contain the recombinant Yarrowia lipolytica-derived hp4d promoter to drive expression of genes of interest, and hence produce the corresponding protein of interest in a growth-phase-dependent manner. Due to the use of said hp4d promoter, the SECRETORY EXPRESSION VECTOR, the SURFACE DISPLAY EXPRESSION VECTOR, and derivatives of either vector that also contain said promoter, are protected by PCT/IB96/00562 to INRA and INA (presently AgroParisTech). This patent application protects the recombinant promoter, the vectors carrying it and the recombinant yeasts transformed with the said vectors.
The SECRETORY EXPRESSION VECTOR and the SURFACE DISPLAY EXPRESSION VECTOR use zeta sequences (Long Terminal Repeats of Ylt1 retrotransposon), which promote homologous (directed) integration of said vectors into the genome of Ylt1-containing Yarrowia lipolytica strains and non-homologous (random) integration of said vectors into the genome of Ylt1-devoid Yarrowia lipolytica strains. Due to the potential use of said zeta sequences for non-homologous integration, the SECRETORY EXPRESSION VECTOR, the SURFACE DISPLAY EXPRESSION VECTOR, and derivatives of either vector that also contain said zeta sequences are also protected by PCT/FR99/02079 to INRA and CNRS. This patent application protects the use of zeta sequences for promoting non-homologous integration into the genome of Ylt1-devoid Yarrowia lipolytica strains, and the recombinant yeasts obtained by such process.
Both the SECRETORY EXPRESSION VECTOR and the SURFACE DISPLAY EXPRESSION VECTOR contain the Ura3d1 marker for complementation of defective uracil auxotrophic markers present in receptive mutant strains. Variations of the vector have been constructed that contain the Leu2 marker for complementation of defective leucine auxotrophic markers present in receptive mutant strains, and are included in this invention. Furthermore, variations of the SECRETORY EXPRESSION VECTOR and the SURFACE DISPLAY EXPRESSION VECTOR which contain a promoter-deficient variation of the Ura marker, Ura3d4, which promotes multiple-copy integration into the genome of receptive strains, are also included in this invention.
Cloning of the Gene Encoding BFDV CP into the SECRETORY EXPRESSION VECTOR and the SURFACE DISPLAY EXPRESSION VECTOR
For cloning of the BFDV CP gene into the SURFACE DISPLAY EXPRESSION VECTOR, endonuclease digestion of the vector containing the capsid gene (provided by GeneArt) as well as the SURFACE DISPLAY EXPRESSION VECTOR was performed, using SfiI and HindIII. The digestion reaction mixtures were electrophoresed on an agarose gel containing ethidium bromide. The appropriate sized bands were excised from the gel and purified using a gel band purification kit (GE Healthcare).
For cloning of the BFDV CP gene into the Secretion EXPRESSION VECTOR, the BFDV CP was amplified from the vector supplied by GeneArt using the primers BFDV SCF (5′-TCAAGGCCACGTGTCTTGTCC-3′)(SEQ ID NO:7) and BFDV SCR (5′-TCCAGGTACCT TACTAGGTGGGGTTGGGGTTG-3′) (SEQ ID NO:8), using Kapa HiFi polymerase. The thermal cycling conditions included an initial denaturation step of 3 min at 95° C., followed by 25 cycles of denaturation at 98° C. for 20 sec, annealing at 60° C. for 15 sec, and extension at 72° C. for 1 min; followed by a final extension step at 72° for 1 min. The PCR products were also sequenced for authenticity verification.
The resultant PCR product (amplicon), referred to as BFDV CP PCR product, was electrophoresed on an agarose gel containing ethidium bromide. The amplicon was excised from the gel and purified using a gel band purification kit (GE Healthcare). The purified amplicon was then phosphorylated using polynucleotide kinase, and sub-cloned into pSMART by ligation. The PCR product contained a new stop codon (TAA) on the 3′ end, followed by a KpnI recognition site.
Endonuclease digestion was performed on the pSMART vector containing the BFDV CP PCR product as well as on the SECRETORY EXPRESSION VECTOR using SfiI and KpnIII. The digestion reaction mixtures were electrophoresed on an agarose gel containing ethidium bromide. The appropriate sized bands were excised from the gel and purified using a gel band purification kit (GE Healthcare).
In both instances, purified BFDV insert DNA fragments were ligated to the appropriately prepared expression vector. Ligation mixtures were used to transform Escherichia coli JM109 cells that had been made competent using rubidium chloride, and transformed cells were streaked out on LB plates supplemented with kanamycin. Single colonies that formed on the LB-kanamycin plates were used to inoculate test tubes containing 5 ml LB broth supplemented with kanamycin, and the tubes were incubated at 37° C. for 16 hours.
Plasmids were isolated from the inoculated cultures using the lysis by a boiling method for mini-preparation of plasmid DNA, or by using the QIAamp DNA mini kit (Qiagen). The presence of the inserted gene of interest in the expression vectors was confirmed by restriction analysis or PCR on isolated plasmids.
Prior to transformation of Yarrowia lipolytica, the isolated recombinant plasmids were digested with NotI, to separate the yeast-integrative cassettes from the bacterial moieties of the vectors, resulting in yeast-integrative cassette devoid of a bacterial genetic material. The yeast-integrative cassette was separated from the bacterial backbone by agarose gel electrophoresis, followed by excision from the gel and purification gel band purification kit (GE Healthcare).
Yarrowia lipolytica strains were transformed using the purified yeast-integrative cassettes according to the methods of Madzak at al. (2005) or Chen et al. (1997). Recipient Yarrowia lipolytica strains were also transformed with the ‘empty’ expression vectors, i.e. expression vectors into which no gene was inserted. Transformants (as shown in
Total genomic DNA (gDNA) was extracted from Yarrowia lipolytica transformants using the method described by Albertyn and Labuschagne (2007). Isolated transformant gDNA samples were used as templates for PCR confirmation of the integration of the BFDV CP gene. This was done using the primers: Chen6560F (GATCCGGCATGCACTGATC) (SEQ ID NO:9) and CM-terX (GAACCTCGTCATTGATGGAC) (SEQ ID NO:10). The forward primer Chen6560F was designed based on the XPR2 promoter region of the vectors, while the reverse primer CM-terX was designed based on the terminator region of the plasmid.
The primer combination therefore amplifies the MCS and parts of the surrounding regions. In the absence of an insert, these primers result in amplicons that are 235 base pairs (bp) in length for the SECRETORY EXPRESSION VECTOR and 575 bp in length for the SURFACE DISPLAY EXPRESSION VECTOR. The difference in length is due to the presence of the GPI-anchored YICWP in the SURFACE DISPLAY EXPRESSION VECTOR. In the presence of the BFDV CP gene within the expression cassette, the primer combination results in amplicons that are 974 bp in length for the SECRETORY EXPRESSION VECTOR and 1316 bp in length for the SURFACE DISPLAY EXPRESSION VECTOR.
The thermal cycling conditions included an initial denaturation step of 2 min at 95° C., followed by 30 cycles of denaturation at 95° C. for 30 sec, annealing at 55° C. for 1 min and extension at 70° C. for 1.30 min; followed by a final extension step at 70° for 5 min. PCR amplifications were also performed using Ready-to-go PCR Beads (GE Healthcare). The resultant amplicons were also sequenced for authenticity verification.
Once transformants had been confirmed to have integrated the cassette, glycerol (15% v/v) was added to culture aliquots, followed by cryopreservation at −80° C. Transformants were revived by streaking from the frozen stocks onto selective YNB-based agar plates, which were incubated at 28-30° C. Pre-cultures of 5 ml YPD were inoculated from the plates, followed by incubation for 16 h on a rotary shaker at 28-30° C. at 160 rpm. The 16 h pre-cultures were used as inoculums for main cultures of 45 ml YPD (hence 1/10 dilution). Main cultures were incubated for 48 h on a rotary shaker at 28-30° C. at 160 rpm.
Cells were harvested by centrifugation at 7000 rcf for 10 min, separating the cells (pellet) from the surrounding medium (supernatant). When using the SURFACE DISPLAY EXPRESSION VECTOR, the cell pellet is washed and resuspended in PBS (5.84 g sodium chloride (NaCl), 4.72 disodium hydrogen phosphate (Na2HPO4) and 2.64 g sodium dihydrogen phosphate (NaH2PO4), pH 7.2), while the supernatant is discarded. When using the SECRETORY EXPRESSION VECTOR, the supernatant is collected for further use while the cellular pellet may be discarded.
Preliminary Tests of Applications
Rapid Plate Agglutination Test for the Detection of Antibodies
For rapid plate agglutination the SURFACE DISPLAY EXPRESSION VECTOR was used. Yeast transformants were harvested by centrifugation at 7000 rcf for 10 min, separating the cells (pellet) from the surrounding medium (supernatant). The cell pellet was washed and resuspended in PBS (5.84 g sodium chloride (NaCl), 4.72 disodium hydrogen phosphate (Na2HPO4) and 2.64 g sodium dihydrogen phosphate (NaH2PO4), pH 7.2). All reagents were allowed to come to room temperature, so as to eliminate the possibility of non-specific reactions. A drop of the antigen (yeast transformant culture) (10 μl) was placed on a clean microscope slide, after which 10 μl of serum was added. The slide was rotated for 30 seconds and the presence or absence of agglutination was noted. A serum sample was considered positive when clear agglutination was observed, as easily visible clumps, whereas the absence of agglutination was interpreted as negative (
Immunofluorescence
Aliquots (20 μl) of yeast transformants were dropped onto cleaned microscope slides and the yeast cells were heat-fixed onto the slides. This was followed by a 15 min blocking step at room temperature (RT) using 20 μl of a solution of 5% skim milk in PBS-Tween. The slides were washed using PBS-Tween, before addition of specific mouse-raised monoclonal antibodies (GenScript), diluted 1:100 in PBS (starting concentration 4.51 mg/ml). The slide was incubated for 1 h at RT. The slides were washed using PBS-Tween, before addition of Fluorochrome-conjugated secondary antibody (FITC) conjugated, anti-mouse IgG (whole molecule, Sigma), diluted 1:1000 in PBS; and further incubation for 1 h at RT in the dark. The slides were washed using PBS-Tween. The slides were immediately viewed using a fluorescence cell imager (ZOE™ Fluorescent cell imager, Bio-Rad laboratories) at an excitation of 480 nm and emission of 517 nm, using the green channel.
Bragg, Robert Richard, Boucher, Charlotte Enastacia, Theron, Chrispian William, Hitzeroth, Arina Corli
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 6083717, | Jun 08 1995 | Institut National de la Recherche Agronomique; Institut National Agronomique Paris- Grignon | Upstream activator sequences and recombinant promoter sequences functional in yarrowia and vectors containing them |
| 6582951, | Sep 01 1998 | Institut National de la Recherche Agronomique - INRA; Centre National de la Recherche Scientifique - CNRS | Method for non-homologous transformation of Yarrowia lipolytica |
| WO12729, | |||
| WO2005082929, | |||
| WO9641889, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Oct 12 2015 | BRAGG, ROBERT RICHARD | University of the Free State | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 039781 | /0952 | |
| Oct 12 2015 | BOUCHER, CHARLOTTE ENASTACIA | University of the Free State | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 039781 | /0952 | |
| Oct 12 2015 | THERON, CHRISPIAN WILLIAM | University of the Free State | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 039781 | /0952 | |
| Oct 12 2015 | HITZEROTH, ARINA CORLI | University of the Free State | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 039781 | /0952 | |
| Sep 15 2016 | University of the Free State | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Oct 27 2021 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Date | Maintenance Schedule |
| May 08 2021 | 4 years fee payment window open |
| Nov 08 2021 | 6 months grace period start (w surcharge) |
| May 08 2022 | patent expiry (for year 4) |
| May 08 2024 | 2 years to revive unintentionally abandoned end. (for year 4) |
| May 08 2025 | 8 years fee payment window open |
| Nov 08 2025 | 6 months grace period start (w surcharge) |
| May 08 2026 | patent expiry (for year 8) |
| May 08 2028 | 2 years to revive unintentionally abandoned end. (for year 8) |
| May 08 2029 | 12 years fee payment window open |
| Nov 08 2029 | 6 months grace period start (w surcharge) |
| May 08 2030 | patent expiry (for year 12) |
| May 08 2032 | 2 years to revive unintentionally abandoned end. (for year 12) |